

QUEST AD-Detect™ Amyloid Beta 42/40 Ratio

Assessing **Alzheimer's risk** starts with a **single blood test**

Almost 600,000 Canadians are living with dementia — and that number is projected to increase 60% by 2030.³ Combined with the increased burden of the COVID-19 pandemic on both patients and caregivers, assessing the risk of Alzheimer's disease has never been more critical.

+ Assess Alzheimer's risk with a simple, accessible, and affordable blood test

QUEST AD-Detect gives you the diagnostic insights you need to assess the risk of Alzheimer's disease (AD). Our high-precision assay, using a **simple blood sample**, is the same type of assay shown to be as effective as traditional cerebrospinal fluid testing and amyloid positron emission tomography (PET) scans.⁴ **A more accessible and affordable option**, plasma testing allows you to establish a baseline and monitor your patients through our Alpha Labs Patient Service Centre locations.

+ Evaluate for Alzheimer's accurately and reliably with ratio of plasma A β 42/40


QUEST AD-Detect assists in the differential diagnosis of AD.^{1,2} QUEST AD-Detect is a high-precision assay of a type shown in a recently published study to be **as effective as traditional methods**.⁴ Internal preliminary studies at Quest have shown the potential for QUEST AD-Detect to be as sensitive as a PET scan.^{1,2,4}

+ Inform potential treatment decisions

In addition to providing accessible insights into the risk of AD, QUEST AD-Detect blood-based biomarker testing may also **help identify patients who are candidates for early antibody treatment**.⁵ As new therapies continue to emerge, antibody treatment may help slow disease progression and improve quality of life.



QUEST AD-Detect™
Amyloid Beta 42/40
Ratio is **analytically
validated** and **less
invasive**^{1,2}


QUEST AD-Detect Amyloid Beta 42/40 vs amyloid-PET status^{1,2}



Identify risk and monitor patients longitudinally

Our enhanced report provides A β 42/40 ratio values from current and 5 past results in 1 table so you can continually monitor your patient's risk.

 **Lower risk of AD: ≥ 0.160**
 **Higher risk of AD: < 0.160**



The QUEST AD-Detect Amyloid Beta 42/40 Ratio is designed to monitor A β 42/40 changes over time to help assess the risk potential of Alzheimer's disease progression. Initial test results may serve as a baseline with which later test results can be compared. There is no one test that can diagnose AD. Results of the QUEST AD-Detect test should be considered in the context of patient management that evaluates symptoms, history and other factors.

The power of Quest Advanced[®] Neurology

Innovative solutions, clinical expertise, and improved experiences for better patient outcomes.



600+ medical experts who are eager to consult with you on next steps for your patients.



Alpha Labs Patient Service Centres (PSCs), meeting patients where they live and work to ensure access to testing.



Alpha Labs Patient Portal gives your patients the ability to take charge of their personal health journey from any device.



Quantum[®] Solutions, a complete cloud EHR, helps keep practices efficient and patient-focused.



Alpha interface with EMRs — making sure you always have seamless access to ordering and results.

Ordering information

Easily order QUEST AD-Detect Amyloid Beta 42/40 Ratio through **Alpha Labs digital portal.**

Test Name	Specimen	Turnaround Time
QUEST AD-Detect Amyloid Beta 42/40 Ratio	Plasma (lavender tube K ₂ EDTA)	3 - 10 days

References

1. Data on file. Quest Diagnostics; 2022.
2. Burnham SC, Fandos N, Fowler C, et al. Longitudinal evaluation of the natural history of amyloid- β in plasma and brain. *Brain Commun.* 2020;2(1):fcaa041. doi:10.1093/braincomms/fcaa041
3. Alzheimer Society of Canada. Dementia Numbers in Canada. <https://alzheimer.ca/en/about-dementia/what-dementia/dementia-numbers-canada>
4. Li Y, Schindler SE, Bollinger J, et al. Validation of plasma amyloid- β 42/40 for detecting alzheimer disease amyloid plaques. *Neurology*. Online ahead of print, December 14, 2021. doi:10.1212/WNL.00000000000013211
5. Cummings J, Lee G, Zhong K, et al. Alzheimer's disease drug development pipeline: 2021. *Alzheimers Dement* (N Y). 2021;7(1):e12179. doi:10.1002/trc2.12179



Alpha Labs

Assess your risk of Alzheimer's with a single blood test

For more information, email us at alpha@alphalabs.ca

1262 Don Mills Road, Toronto, ON M3B 2W7 Canada | alphalabs.ca